Pacer Advisors Inc. Has $117.85 Million Position in United Therapeutics Corporation $UTHR

Posted by Geri Gentry on Jun 19th, 2026

Pacer Advisors Inc. reduced its holdings in United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 28.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 241,872 shares of the biotechnology company’s stock after selling 97,199 shares during the period. Pacer Advisors Inc.’s holdings in United Therapeutics were worth $117,852,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Torren Management LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at about $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after acquiring an additional 56 shares during the last quarter. Entrust Financial LLC bought a new stake in United Therapeutics during the fourth quarter worth about $31,000. Wilmington Savings Fund Society FSB boosted its position in United Therapeutics by 125.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after purchasing an additional 49 shares during the last quarter. Finally, Harbor Capital Advisors Inc. acquired a new position in United Therapeutics during the fourth quarter valued at approximately $48,000. 94.08% of the stock is owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In related news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Monday, April 6th. The stock was sold at an average price of $558.40, for a total value of $5,584,000.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,540,358.40. This represents a 34.63% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 644,468 shares of company stock worth $364,004,497. 8.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several research analysts have weighed in on the company. HC Wainwright boosted their price target on United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a research report on Tuesday, March 31st. Royal Bank Of Canada cut their price objective on United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. UBS Group raised their target price on shares of United Therapeutics from $655.00 to $705.00 and gave the company a “buy” rating in a research note on Thursday, March 5th. Weiss Ratings restated a “buy (b)” rating on shares of United Therapeutics in a report on Thursday, June 11th. Finally, Jefferies Financial Group reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Check Out Our Latest Research Report on United Therapeutics

United Therapeutics Stock Performance

United Therapeutics stock opened at $536.59 on Friday. The stock has a 50-day simple moving average of $565.37 and a 200 day simple moving average of $523.32. The stock has a market capitalization of $22.78 billion, a P/E ratio of 19.81, a PEG ratio of 1.80 and a beta of 0.57. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last released its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to the consensus estimate of $797.40 million. During the same quarter in the prior year, the company earned $6.63 EPS. United Therapeutics’s quarterly revenue was down 1.6% on a year-over-year basis. Research analysts forecast that United Therapeutics Corporation will post 26.84 earnings per share for the current year.

United Therapeutics Company Profile

(Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.